The mission of The DOLF Project is to develop and test improved treatments for onchocerciasis and lymphatic filariasis that will enhance efforts to control and eliminate these important neglected tropical diseases.
NEWS & EVENTS
DOLF Team receives a $1.8 million Bill and Melinda Gates Foundation Grant to Explore Lymphatic Filariasis Elimination in Indonesia
Over a decade ago, Indonesia had one of the largest populations endemic for lymphatic filariasis (LF) in the world with 50% of the districts endemic for this mosquito borne disease. The country consists of 6,000 inhabited island and stretches over 3,000 miles from east to west. While some districts have eliminated LF by mass drug […]
The DOLF Team’s Work to Improve Prospects for Elimination of LF Featured in a Special Supplement Published in the Am. J. Trop. Med. Hyg. (March 2022)
The DOLF project (www.dolfproject.wustl.edu) led clinical trials and community studies of the safety and efficacy of a single-dose triple-drug therapy (IDA) for Lymphatic Filariasis (LF). IDA is now being used in mass drug administration (MDA) programs in many countries to accelerate LF elimination. This work was supported by grants from the Bill & Melinda Gates […]
Development of new treatments for Riverblindness
Development of new treatments for Riverblindness: Facilitated histological assessment of Onchocerca volvulus nodules to detect treatment effects on adult worms Adult O. volvulus worms reside in subcutaneous nodules and can live up to 15 years. It requires special expert knowledge to differentiate natural morphological changes during its life span from changes induced by anti-filarial drugs […]
